2/27
08:50 am
urgn
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC [Yahoo! Finance]
Medium
Report
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC [Yahoo! Finance]
2/27
08:30 am
urgn
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
Medium
Report
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
2/24
04:25 pm
urgn
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Low
Report
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
2/24
04:05 pm
urgn
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
Low
Report
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
2/23
08:00 am
urgn
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
Low
Report
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
2/15
08:11 pm
urgn
UroGen Pharma CEO Touts ZUSDURI Launch Momentum, J-Code Boost and Billion-Plus Peak Sales Target [Yahoo! Finance]
Low
Report
UroGen Pharma CEO Touts ZUSDURI Launch Momentum, J-Code Boost and Billion-Plus Peak Sales Target [Yahoo! Finance]
2/4
08:00 am
urgn
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
Medium
Report
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
1/23
08:04 am
urgn
Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $33.00 price target on the stock.
Neutral
Report
Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $33.00 price target on the stock.
1/6
08:46 am
urgn
UroGen Pharma says permanent J Code for ZUSDURI now in effect [Yahoo! Finance]
Low
Report
UroGen Pharma says permanent J Code for ZUSDURI now in effect [Yahoo! Finance]
1/5
08:42 am
urgn
Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $33.00 price target on the stock.
Low
Report
Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $33.00 price target on the stock.
1/5
08:00 am
urgn
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
High
Report
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
12/31
07:03 pm
urgn
Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
Medium
Report
Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
12/26
02:07 pm
urgn
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally [Yahoo! Finance]
Low
Report
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally [Yahoo! Finance]
12/5
08:00 am
urgn
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)